Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs

Executive Summary

In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.

Advertisement

Related Content

Boston Bags Assets From GSK and Novartis
Roivant Splashes Cash Again To License GSK Skin Disorder Drug
Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally
Deal Watch: Opportunity Knocks For Partnerships In Asia
GSK Most Likely To Buy Pfizer's Consumer Business – Is It A Step In Wrong Direction?
Digital Gets Top Billing As Novartis CEO Wields Management Broom
Walmsley Takes On Oncology: Can GSK Become A Power Player?
GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In
GSK's Immunology Strategy Edges Closer To Delivering
Witty’s Bonus Slashed As GSK Recovers From China Scandal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel